Phase I/II Study of Vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]), Temozolomide, and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma.

Trial Profile

Phase I/II Study of Vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]), Temozolomide, and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma.

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 27 Jun 2017

At a glance

  • Drugs Vorinostat (Primary) ; Temozolomide
  • Indications Astrocytoma; Glioblastoma; Gliosarcoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2016 Results assessing RNAseq-signatures (n=76) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
    • 03 Jun 2014 Interim results presented at the 50th Annual Meeting of the American Society of Clinical Oncology.
    • 01 Jul 2013 Planned End Date changed from 1 Sep 2013 to 1 Feb 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top